Video

Genomic Classifier in Prostate Cancer: Metastatic VL

Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard Details Nicholas James and Gerhardt Attard discuss findings from the STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. They explore the use of the Decipher® genomic classifier as a prognostic and predictive tool for treatment decisions in metastatic prostate cancer. The conversation covers the test's ability to identify patients who are likely to benefit from abiraterone and, more...
Utilizing the Decipher® mRNA Score for Risk Stratification in mHSPC - David Morris and Ashley Ross Details Ashley Ross and David Morris discuss the use of the Decipher ® Genomic Classifier in metastatic hormone-sensitive prostate cancer (mHSPC). They explore how Decipher ® can help stratify patients and guide treatment decisions, particularly in choosing between monotherapy, doublet, or triplet therapies. The discussion covers the STAMPEDE trial data, showing Decipher's ® ability to predict treatment s...